Business
ORT_B: Revenue up, EBITDA positive, and US commercialization underway pending approvals
ORT_B: Revenue up, EBITDA positive, and US commercialization underway pending approvals
About this update from Ortoma Ab Class B
Revenue grew 29% to SEK 49.1 million in 2024, with EBITDA turning positive and net loss narrowing. Commercialization advanced in the US and Japan, with regulatory approvals key for 2025 launches. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.